New once-daily inhaler aims to boost exercise ability in rare lung disease
NCT ID NCT07481981
First seen Mar 29, 2026 · Last updated Jun 19, 2026 · Updated 18 times
Summary
This study tests an inhaled medication called treprostinil palmitil taken once daily to see if it helps adults with pulmonary arterial hypertension (PAH) walk farther. PAH is a serious condition where high blood pressure in the lungs makes it hard to breathe and exercise. The trial will compare the drug to a placebo over 24 weeks in about 344 participants, measuring changes in a 6-minute walk test and other health indicators.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
USA007
RECRUITINGAnderson, South Carolina, 29621, United States
-
USA008
RECRUITINGSanta Barbara, California, 93105, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.